322 related articles for article (PubMed ID: 1185108)
41. The role of properdin in the assembly of the alternative pathway C3 convertases of complement.
Hourcade DE
J Biol Chem; 2006 Jan; 281(4):2128-32. PubMed ID: 16301317
[TBL] [Abstract][Full Text] [Related]
42. Activation of the alternative (properdin) pathway by divalent cations.
Lew FT; Yukiyama Y; Waks HS; Osler AG
J Immunol; 1975 Sep; 115(3):884-8. PubMed ID: 807649
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
Sahu A; Kay BK; Lambris JD
J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
[TBL] [Abstract][Full Text] [Related]
44. The alternative pathway of complement activation.
Götze O; Müller-Eberhard HJ
Adv Immunol; 1976; 24():1-35. PubMed ID: 798473
[No Abstract] [Full Text] [Related]
45. Interaction of beta1H globulin with cell-bound C3b: quantitative analysis of binding and influence of alternative pathway components on binding.
Conrad DH; Carlo JR; Ruddy S
J Exp Med; 1978 Jun; 147(6):1792-1805. PubMed ID: 567241
[TBL] [Abstract][Full Text] [Related]
46. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3.
Pangburn MK; Schreiber RD; Müller-Eberhard HJ
J Exp Med; 1981 Sep; 154(3):856-67. PubMed ID: 6912277
[TBL] [Abstract][Full Text] [Related]
47. Insights Into Enhanced Complement Activation by Structures of Properdin and Its Complex With the C-Terminal Domain of C3b.
van den Bos RM; Pearce NM; Granneman J; Brondijk THC; Gros P
Front Immunol; 2019; 10():2097. PubMed ID: 31552043
[TBL] [Abstract][Full Text] [Related]
48. Structural Basis for Properdin Oligomerization and Convertase Stimulation in the Human Complement System.
Pedersen DV; Gadeberg TAF; Thomas C; Wang Y; Joram N; Jensen RK; Mazarakis SMM; Revel M; El Sissy C; Petersen SV; Lindorff-Larsen K; Thiel S; Laursen NS; Fremeaux-Bacchi V; Andersen GR
Front Immunol; 2019; 10():2007. PubMed ID: 31507604
[TBL] [Abstract][Full Text] [Related]
49. Properdin binding to complement activating surfaces depends on initial C3b deposition.
Harboe M; Johnson C; Nymo S; Ekholt K; Schjalm C; Lindstad JK; Pharo A; Hellerud BC; Nilsson Ekdahl K; Mollnes TE; Nilsson PH
Proc Natl Acad Sci U S A; 2017 Jan; 114(4):E534-E539. PubMed ID: 28069958
[TBL] [Abstract][Full Text] [Related]
50. Chemotactic activity derived from interaction of factors D and B of the properdin pathway with cobra venom factor or C3B.
Ruddy S; Austen KF; Goetzl EJ
J Clin Invest; 1975 Mar; 55(3):587-92. PubMed ID: 1167871
[TBL] [Abstract][Full Text] [Related]
51. A novel mechanism of complement inhibition unmasked by a tick salivary protein that binds to properdin.
Tyson KR; Elkins C; de Silva AM
J Immunol; 2008 Mar; 180(6):3964-8. PubMed ID: 18322205
[TBL] [Abstract][Full Text] [Related]
52. Properdin binds to late apoptotic and necrotic cells independently of C3b and regulates alternative pathway complement activation.
Xu W; Berger SP; Trouw LA; de Boer HC; Schlagwein N; Mutsaers C; Daha MR; van Kooten C
J Immunol; 2008 Jun; 180(11):7613-21. PubMed ID: 18490764
[TBL] [Abstract][Full Text] [Related]
53. Activation of the complement and properdin systems in rheumatoid arthritis.
Ruddy S; Austen KF
Ann N Y Acad Sci; 1975 Jun; 256():96-104. PubMed ID: 1099964
[TBL] [Abstract][Full Text] [Related]
54. Identification of a novel mode of complement activation on stimulated platelets mediated by properdin and C3(H2O).
Saggu G; Cortes C; Emch HN; Ramirez G; Worth RG; Ferreira VP
J Immunol; 2013 Jun; 190(12):6457-67. PubMed ID: 23677468
[TBL] [Abstract][Full Text] [Related]
55. Soluble collectin-12 mediates C3-independent docking of properdin that activates the alternative pathway of complement.
Zhang J; Song L; Pedersen DV; Li A; Lambris JD; Andersen GR; Mollnes TE; Ma YJ; Garred P
Elife; 2020 Sep; 9():. PubMed ID: 32909942
[TBL] [Abstract][Full Text] [Related]
56. Complement fixation by solid phase immune complexes. Reduced capacity in SLE sera.
Baatrup G; Jonsson H; Sjöholm A; Sturfelt G; Svehag SE
J Clin Lab Immunol; 1988 Jun; 26(2):73-9. PubMed ID: 3264027
[TBL] [Abstract][Full Text] [Related]
57. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
Brown EJ; Ramsey J; Hammer CH; Frank MM
J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
[TBL] [Abstract][Full Text] [Related]
58. Modulation of C3b hemolytic activity by a plasma protein distinct from C3b inactivator.
Whaley K; Ruddy S
Science; 1976 Sep; 193(4257):1011-3. PubMed ID: 948757
[TBL] [Abstract][Full Text] [Related]
59. Properdin factor D. II. Activation to D by properdin.
Fearon DT; Austen KF; Ruddy S
J Exp Med; 1974 Aug; 140(2):426-36. PubMed ID: 4211020
[TBL] [Abstract][Full Text] [Related]
60. The cofactors required by C3 nephritic factor to generate a C3 convertase in vitro.
Amos N; Sissons JG; Girard JF; Lachmann PJ; Peters DK
Clin Exp Immunol; 1976 Jun; 24(3):474-82. PubMed ID: 939051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
